Journal
JOURNAL OF MOLECULAR MEDICINE-JMM
Volume 91, Issue 12, Pages 1333-1342Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s00109-013-1085-2
Keywords
Aptamer; Biosensors; Drug delivery; In vitro selection; Modified nucleic acid; SELEX
Funding
- Department of Science and Technology (DST), Govt. of India
Ask authors/readers for more resources
Aptamers are single-stranded oligonucleotides that fold into well-defined three-dimensional shapes, allowing them to bind their targets with high affinity and specificity. They can be generated through an in vitro process called Systemic Evolution of Ligands by Exponential Enrichment and applied for specific detection, inhibition, and characterization of various targets like small organic and inorganic molecules, proteins, and whole cells. Aptamers have also been called chemical antibodies because of their synthetic origin and their similar modes of action to antibodies. They exhibit significant advantages over antibodies in terms of their small size, synthetic accessibility, and ability to be chemically modified and thus endowed with new properties. The first generation of aptamer drug Macugen was available for public use within 25 years of the discovery of aptamers. With others in the pipeline for clinical trials, this emerging field of medical biotechnology is raising significant interest. However, aptamers pose different problems for their development than for antibodies that need to be addressed to achieve practical applications. It is likely that current developments in aptamer engineering will be the basis for the evolution of improved future bioanalytical and biomedical applications. The present review discusses the development of aptamers for therapeutics, drug delivery, target validation and imaging, and reviews some of the challenges to fully realizing the promise of aptamers in biomedical applications.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available